CORRIGENDUM TO: [Pharmacy Formulas. - 2021. - Vol. 3. - N. 1. - P. 66-75. doi: 10.17816/phf60598]

2021 ◽  
Vol 3 (2) ◽  
pp. 99-99
Author(s):  
Lyudmila K. Peshekhonova ◽  
Dmitry V. Peshekhonov ◽  
Alexander O. Pyatibrat ◽  
Nikolay G. Vengerovich
Keyword(s):  
Acute Exacerbation ◽  
Dosage Forms ◽  
Supplementary Prescribing

Correction in Peshekhonova L.K., Peshekhonov D.V., Pyatibrat A.O., Vengerovich N.Г. Comparison of the effectiveness of supplementary prescribing the chonodoprotector Mucosat in the oral and parenteral dosage forms during the acute exacerbation of osteoarthritis // Pharmacy Formulas. 2021. Vol. 3. N. 1. P. 6675. doi: https://doi.org/10.17816/phf60598.

Policy, Practice and Education 2004: Implementation: cystic fibrosis

2004 ◽  
Vol 1 (5) ◽  
pp. 2-2
Keyword(s):  
Cystic Fibrosis ◽  
Acute Exacerbation ◽  
Policy Practice ◽  
Nurse Prescribing ◽  
Supplementary Prescribing

Donaghy B. Supplementary prescribing in cystic fibrosis: responding to an acute exacerbation. Nurse Prescribing 2004; 2(2): 84–85.

scholarly journals Comparison of the effectiveness of supplementary prescribing the chonodoprotector Mucosat in the oral and parenteral dosage forms during the acute exacerbation of osteoarthritis

2021 ◽  
Author(s):  
Lyudmila K. Peshekhonova ◽  
Dmitry V. Peshekhonov ◽  
Alexander O. Pyatibrat ◽  
Nikolai Vengerovich
Keyword(s):  
Physical Activity ◽  
Therapeutic Effect ◽  
Study Groups ◽  
Evidence Base ◽  
Dosage Forms ◽  
Supplementary Prescribing ◽  
Group Homogeneity ◽  
Inflammatory Drugs ◽  
Observational Design

The study aims to compare the methods of Mucosat drug use and administration for achieving the desired therapeutic effect in the treatment of osteoarthritis. Despite extensive evidence base, improving complex therapy schemes for the use of successive and complementary dosage forms with the appropriate drug administration and use in order to achieve the desired therapeutic effect is still a valid aim. In the course of the study, 50 knee osteoarthritis patients were examined and treated during the period from November, 2019 to April, 2020. A clinical trial was carried out to assess Mucosat oral and parental administration effectiveness in the patients comparing their physical activity, functional ability and quality of life. The number of undesired side effects identified the degree of therapeutic tolerance against the comorbid diseases identified. A comparison of the therapeutic efficacy and tolerability of Musocat intramuscular and capsule administration, patient compliance, the need to take non-steroidal anti-inflammatory drugs (NSAIDs) was drawn. Statistica 12 and Excel 2016 were used to carry out the statistical analysis of the data obtained. The study was generally marked by diagnostic accuracy with the use of modern methods, group homogeneity, prospective observational design. By the time of pharmacotherapy completion, physical activity has become optimal in the study groups. However, parental therapy had significantly higher effectiveness than the oral one on all the subscales. As a result, articular syndrome severity has been reduced and the functional state of the joints expanded. The study has shown that Mucosat demonstrates high efficacy both in injectable solution and capsule dosage forms as a basic chondroprotective drug. Mucosat pharmacotherapy course has contributed to permanent discontinuation of NSAIDs before completion of the therapy. The superiority of Mucosat parenteral administration over the oral one has been proven.

Serum Magnesium Levels in Exacerbation of COPD: A Single Centre Prospective Study from Kashmir, India.

JMS SKIMS ◽  
2010 ◽  
Vol 13 (1) ◽  
pp. 15-19
Author(s):  
Bashir Ahmed Shah ◽  
Muzafar Ahmed Naik ◽  
Sajjad Rajab ◽  
Syed Muddasar ◽  
Ghulam Nabi Dhobi ◽  
...  
Keyword(s):  
Acute Exacerbation ◽  
Serum Magnesium ◽  
Stage Iii ◽  
Advanced Stage ◽  
Copd Exacerbation ◽  
Post Discharge ◽  
Duration Of Symptoms ◽  
Copd Patients ◽  
Exacerbation Of Copd ◽  
Time Of Admission

Objective: To study the significance of serum magnesium levels during COPD exacerbation and stability.Materials & Methods: The patient population consisted of all patients of COPD admitted as acute exacerbation as defined by the Anthonisens criteria, from June 2006 to may 2008. Same patients one month post discharge presenting to the OPD for routine check up as stable COPD served as controls. Results: A total number of 77 patients of COPD presenting as acute exacerbation were included in the study. The incidence of Hypomagnesaemia was 33.8% at admission; 5% at discharge and 4% at one month of post discharge in COPD patients. The mean serum magnesium levels were significantly lower in cases than controls (1.88±0.67mg/ dl V/S 2.3±0.36mg/dl; p<0.0001). Also, hypomagnesemia was present in higher number of cases (22/77, 33.8%) compared to controls, 3/75, 4.0%; (p<0.0001). Patients of COPD with acute exacerbation and hypomagnesemia, had longer duration of symptoms and had advanced stage III of COPD (p<0.001); and had raised mean corpuscle volume (p<0.045) and longer hospital stay (p<0.008).  Conclusion: We conclude COPD exacerbation is associated with hypomagnesemia. The duration of symptoms of more than 8 days, advanced stage of COPD (stage III) and raised MCV were associated with hypomagnesemia. We recommend to monitor serum magnesium levels in COPD patients with acute exacerbation at the time of admission and during their stay in the hospital.J Med Sci.2010;13(1);15-19

A validated densitometric TLC method for analysis of cefuroxime axetil and potassium clavulanate in combined tablet dosage forms

2010 ◽  
Vol 22 (1) ◽  
pp. 91-97 ◽  
Author(s):  
M. R. Sengar ◽  
S. V. Gandhi ◽  
U. P. Patil ◽  
V. S. Rajmane ◽  
K. G. Bothara
Keyword(s):  
Cefuroxime Axetil ◽  
Dosage Forms ◽  
Potassium Clavulanate ◽  
Tablet Dosage

Pharmaceutical Approaches to Preparing Pelletized Dosage Forms Using the Extrusion-Spheronization Process

2007 ◽  
Vol 24 (1) ◽  
pp. 1-40 ◽  
Author(s):  
Namrata R. Trivedi ◽  
Maria Gerald Rajan ◽  
James R. Johnson ◽  
Atul J. Shukla
Keyword(s):  
Dosage Forms ◽  
Extrusion Spheronization
Sign in / Sign up

Export Citation Format

Share Document